Budesonide (800 and 1600 μg/day) via Easyhaler® has equivalent systemic activity to the same doses via Turbuhaler®

K. M. Hämäläinen, A. Malinen, M. Granander, P. Toivanen (Kuopio, Finland)

Source: Annual Congress 2001 - New developments in inhaler delivery systems
Session: New developments in inhaler delivery systems
Session type: Thematic Poster Session
Number: 710
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
K. M. Hämäläinen, A. Malinen, M. Granander, P. Toivanen (Kuopio, Finland). Budesonide (800 and 1600 μg/day) via Easyhaler® has equivalent systemic activity to the same doses via Turbuhaler®. Eur Respir J 2001; 16: Suppl. 31, 710

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The anti-inflammatory effect of budesonide 800 μg/day via Easyhaler® compared with the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 337s
Year: 2001

Budesonide 800 μg/day via Easyhaler® is as safe and effective as the same dose of budesonide via Turbuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 100s
Year: 2001

Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Year: 2007


Lower systemic exposure to corticosteroid for fluticasone propionate/salmeterol (500/50mcg bd) compared to budesonide/formoterol (400/12mcg bd) administered via combination dry powder inhalers in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Comparison of ciclesonide (MDI) once daily and fluticasone propionate (Diskus®) twice daily in the treatment of patients with moderate asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 666s
Year: 2006

Same minimal effective dose of budesonide Turbuhaler® and fluticasone Diskus®/Accuhaler® in adult asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 158s
Year: 2001

A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Comparison of a combination of HFA propelled fluticasone 125 mcg and salmeterol 25 mcg (FP + SM 125/25) with two separate single preparation pMDIs
Source: Eur Respir J 2007; 30: Suppl. 51, 614s
Year: 2007

12 weeks comparing salmeterol/fluticasone proprionate (SFC, 50/100 microg b.d. diskus) versus fluticasone proprionate (FP, 250 microg b.i.diskus) as first-line regular asthma treatment
Source: Eur Respir J 2003; 22: Suppl. 45, 236s
Year: 2003

Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Addition of an extra dose of salmeterol (S) diskus to conventional dose of S diskus in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 177s
Year: 2001

Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

QVAR pMDI is more cost-effective than fluticasone propionate (FP) or CFC-beclometasone dipropionate (BDP) PMDI in a real-life asthmatic population receiving an increase in ICS dose
Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care
Year: 2009

Lung bioavailability of beclometasone dipropionate and formoterol fumarate fixed dose combination administered using a pMDI or a novel DPI: NEXThaler®
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012


Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to in vitro fine particle dose proportionality
Source: Eur Respir J 2001; 18: Suppl. 33, 157s
Year: 2001

Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS)
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005